Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Antiretroviral therapy (ART) has dramatically changed both mortality and morbidity associated with HIV infection, but treatment is lifelong and costly. The greatest disease burden, affecting 23 million people, is in Sub Saharan Africa where ART coverage for those in need is estimated at below 60%.1 The continued high rate of new infections demands urgent intervention, and, in the absence of an effective prophylactic vaccine, studies using ART to prevent HIV acquisition among uninfected individuals have been undertaken.
Baeten and colleagues report the results of a randomised trial among 4747 HIV-1–serodiscordant heterosexual couples from Kenya and Uganda comparing prophylactic single agent tenofovir (TDF), with tenofovir–emtricitabine (TDF-FTC) against placebo for pre-exposure prophylaxis …
Competing interests None.